{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:51:02Z","timestamp":1793969462037,"version":"4.8.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.esmoop.2022.100605","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T21:20:46Z","timestamp":1667856046000},"page":"100605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review"],"prefix":"10.1016","volume":"7","author":[{"given":"L.","family":"Eng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nagee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fazelzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chaiton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Truscott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Papadakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100605_bib1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1078-0432.CCR-13-0666","article-title":"Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement","volume":"19","author":"Toll","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100605_bib2","series-title":"The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General","year":"2014"},{"key":"10.1016\/j.esmoop.2022.100605_bib3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/SLA.0b013e31824f632d","article-title":"Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review","volume":"255","author":"Sorensen","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.esmoop.2022.100605_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/SLA.0b013e3182708cc5","article-title":"Tobacco smoking and postoperative outcomes after colorectal surgery","volume":"258","author":"Sharma","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.esmoop.2022.100605_bib5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1259\/0007-1285-63-751-554","article-title":"Smoking and mucosal reactions to radiotherapy","volume":"63","author":"Rugg","year":"1990","journal-title":"Br J Radiol"},{"key":"10.1016\/j.esmoop.2022.100605_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2011.06.010","article-title":"Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer","volume":"101","author":"Alsadius","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib7","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2002.10.128","article-title":"Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer","volume":"20","author":"Eifel","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100605_bib9","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.2006.09.6115","article-title":"Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia","volume":"25","author":"van der Bol","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100605_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.2012-0335","article-title":"Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib","volume":"19","author":"Keizman","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100605_bib12","first-page":"1","article-title":"Nicotine and lung cancer","volume":"12","author":"Warren","year":"2013","journal-title":"J\u00a0Carcinog"},{"key":"10.1016\/j.esmoop.2022.100605_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1165\/rcmb.2007-0277OC","article-title":"Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer","volume":"40","author":"Zhang","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.esmoop.2022.100605_bib14","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1634\/theoncologist.2011-0169","article-title":"The effect of cigarette smoking on cancer treatment-related side effects","volume":"16","author":"Peppone","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100605_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2008.02.013","article-title":"Primary causes of death after permanent prostate brachytherapy","volume":"72","author":"Bittner","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2022.100605_bib16","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1158\/1055-9965.EPI-05-0224","article-title":"Smoking, the missing drug interaction in clinical trials: ignoring the obvious","volume":"14","author":"Gritz","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.esmoop.2022.100605_bib17","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.2011.40.8815","article-title":"Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials","volume":"30","author":"Peters","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib18","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1002\/cncr.30223","article-title":"Tobacco assessment in completed lung cancer treatment trials","volume":"122","author":"Peters","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/jnci\/88.21.1550","article-title":"Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial","volume":"88","author":"Omenn","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2022.100605_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJM199605023341802","article-title":"Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease","volume":"334","author":"Omenn","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100605_bib21","doi-asserted-by":"crossref","first-page":"15061","DOI":"10.18632\/oncotarget.24589","article-title":"Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer","volume":"9","author":"Tibau","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2022.100605_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"10.1016\/j.esmoop.2022.100605_bib23","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/j.cllc.2018.04.018","article-title":"Chemoradiotherapy in elderly patients with non-small-cell lung cancer: long-term follow-up of a randomized trial (JCOG0301)","volume":"19","author":"Atagi","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2017.01.022","article-title":"Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB\/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance)","volume":"12","author":"Baggstrom","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.lungcan.2018.03.005","article-title":"Canadian Cancer Trials Group (CCTG) IND211: a randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy","volume":"120","author":"Bradbury","year":"2018","journal-title":"Lung Cancer"},{"issue":"29","key":"10.1016\/j.esmoop.2022.100605_bib27","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.19.01007","article-title":"Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"37","author":"Chera","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2022.100605_bib28","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-18-2860","article-title":"Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase III trial","volume":"25","author":"Eberst","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100605_bib29","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib30","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1200\/JCO.2017.74.1165","volume":"35","author":"Ganz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100605_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1470-2045(17)30694-0","article-title":"Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study","volume":"19","author":"Herbst","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2018.11.041","article-title":"Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: a randomized phase II (RENO study)","volume":"135","author":"Isla","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jgo.2016.05.002","article-title":"Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study","volume":"8","author":"Karampeazis","year":"2017","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib35","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100605_bib36","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.19.01006","article-title":"Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer: ECOG-ACRIN 5508","volume":"37","author":"Ramalingam","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib37","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2017.76.2518","article-title":"Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial","volume":"36","author":"Tao","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib38","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100605_bib39","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S1470-2045(17)30691-5","article-title":"Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial","volume":"18","author":"Wakelee","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cllc.2017.06.016","article-title":"Paired phase II studies of erlotinib\/bevacizumab for advanced bronchioloalveolar carcinoma or never smokers with advanced non-small-cell lung cancer: SWOG S0635 and S0636 trials","volume":"19","author":"West","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2016.07.020","article-title":"Quality of life and performance status from a substudy conducted within a prospective phase 3 randomized trial of concurrent standard radiation versus accelerated radiation plus cisplatin for locally advanced head and neck carcinoma: NRG oncology RTOG 0129","volume":"97","author":"Xiao","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2022.100605_bib42","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(17)30447-3","article-title":"Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial","volume":"18","author":"Alderson","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib43","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/annonc\/mdx351","article-title":"Late toxicities and clinical outcome at 5 years of the ACCORD 12\/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer","volume":"28","author":"Azria","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib44","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib45","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1002\/cam4.2311","volume":"8","author":"Charton","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2022.100605_bib46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.01.081","article-title":"Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: results from a randomised phase III trial (JASPAC 01)","volume":"93","author":"Hagiwara","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib48","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","article-title":"Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033","volume":"3","author":"Heinrich","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib49","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ijrobp.2018.04.013","article-title":"A\u00a0randomized phase 2 trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal cancer: KCSG CO 14-03","volume":"101","author":"Kim","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2022.100605_bib50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1634\/theoncologist.2018-0142","article-title":"A\u00a0Phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01)","volume":"24","author":"Lee","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100605_bib51","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib52","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1634\/theoncologist.2017-0640","article-title":"Randomized phase II trial of CapOX plus bevacizumab and CapIRI plus bevacizumab as first-line treatment for Japanese patients with metastatic colorectal cancer (CCOG-1201 Study)","volume":"23","author":"Nakayama","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100605_bib53","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","article-title":"Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial","volume":"3","author":"Suntharalingam","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","article-title":"Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial","volume":"4","author":"Yamada","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2022.100605_bib55","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1200\/JCO.18.01138","article-title":"Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial","volume":"37","author":"Yoshida","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib56","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(18)30383-2","article-title":"Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial","volume":"4","author":"Yoshikawa","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2022.100605_bib57","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ijrobp.2017.07.045","article-title":"Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the north central cancer treatment group N0574 (Alliance) randomized controlled trial","volume":"99","author":"Churilla","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2022.100605_bib58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejca.2017.05.037","article-title":"Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial","volume":"83","author":"Ferry","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib59","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/jamaoncol.2018.6752","article-title":"Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial","volume":"5","author":"Bruner","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib60","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2018.10.005","article-title":"Phase 2 randomized study of radiation therapy and 3-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients","volume":"103","author":"Carles","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2022.100605_bib61","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","article-title":"Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"18","author":"Duchesne","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijrobp.2018.06.008","article-title":"Patient reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"102","author":"Lukka","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2022.100605_bib63","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib64","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 Trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib65","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.esmoop.2022.100605_bib66","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib67","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2017.77.4273","article-title":"Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203","volume":"36","author":"Klopp","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib68","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100605_bib69","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2018.12.008","article-title":"A\u00a0randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"152","author":"Matulonis","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib70","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/annonc\/mdx049","article-title":"A\u00a0phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study","volume":"28","author":"Monk","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib71","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/annonc\/mdy062","article-title":"Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer","volume":"29","author":"Piccirillo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib72","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study","volume":"35","author":"Pignata","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2019.03.240","volume":"154","author":"Spirtos","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib74","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/annonc\/mdy036","article-title":"Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study (JCOG0701)","volume":"29","author":"Kodaira","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib75","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/bloodadvances.2018026625","article-title":"Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML","volume":"3","author":"Bassan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.esmoop.2022.100605_bib76","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib77","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100605_bib78","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2352-3026(17)30235-1","article-title":"Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study","volume":"5","author":"Dartigeas","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100605_bib79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100605_bib80","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib81","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"31","key":"10.1016\/j.esmoop.2022.100605_bib82","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib83","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100605_bib84","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib85","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib86","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/leu.2017.283","article-title":"High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG","volume":"32","author":"Sakura","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.esmoop.2022.100605_bib87","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1016\/S2352-3026(18)30155-8","article-title":"Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial","volume":"5","author":"Watanabe","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100605_bib88","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2352-3026(19)30051-1","article-title":"Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial","volume":"6","author":"Xu","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2022.100605_bib89","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1200\/JCO.18.00982","article-title":"Patient-reported outcomes over 5 years after whole- Or partial-breast radiotherapy: longitudinal analysis of the import low (CRUK\/06\/003) phase III randomized controlled trial","volume":"37","author":"Bhattacharya","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib90","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1470-2045(17)30404-7","volume":"18","author":"Cameron","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib91","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejca.2018.06.025","article-title":"UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer","volume":"103","author":"Campone","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib92","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","article-title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"390","author":"Coles","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100605_bib93","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1470-2045(17)30319-4","article-title":"Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial","volume":"18","author":"Earl","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib94","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djx258","article-title":"Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results","volume":"110","author":"Gluz","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2022.100605_bib95","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib96","first-page":"29","volume":"39","author":"Kim","year":"2019","journal-title":"Cancer Commun"},{"key":"10.1016\/j.esmoop.2022.100605_bib97","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2018.02.016","article-title":"A\u00a0randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)","volume":"94","author":"Lindman","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib98","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","article-title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Mamounas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib99","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1200\/JCO.2018.79.2028","article-title":"Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103)","volume":"36","author":"Miller","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib100","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(18)30195-5","article-title":"Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial","volume":"19","author":"Schafer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib101","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-018-4713-2","volume":"169","author":"Wagner","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2022.100605_bib102","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib103","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.esmoop.2022.100605_bib104","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in Ewing Sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11060-016-2288-5","article-title":"NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma","volume":"131","author":"Gilbert","year":"2017","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib106","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib107","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100605_bib108","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.2018.78.6186","article-title":"Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): A phase III, noninferiority, randomized controlled trial","volume":"36","author":"Kayama","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib109","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijrobp.2018.11.008","article-title":"Phase 2 study of radiation therapy plus low-dose temozolomide followed by temozolomide and irinotecan for glioblastoma: NRG Oncology RTOG trial 0420","volume":"103","author":"Lieberman","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.esmoop.2022.100605_bib110","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","article-title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study","volume":"390","author":"van den Bent","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100605_bib111","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S1470-2045(18)30362-0","article-title":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p\/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial","volume":"19","author":"van den Bent","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib112","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.2016.70.4072","article-title":"Phase III prospective randomized comparison trial of depot octreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518","volume":"35","author":"Yao","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib113","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100605_bib114","article-title":"Cancer patient attitudes and preferences towards smoking status assessment","volume":"36","author":"Eng","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib115","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/JTO.0b013e318288dc96","article-title":"Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients","volume":"8","author":"Warren","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib116","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/cncr.29964","article-title":"Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research","volume":"122","author":"Land","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2022.100605_bib117","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1158\/1078-0432.CCR-16-0104","article-title":"Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research","volume":"22","author":"Land","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100605_bib118","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100605_bib119","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100605_bib120","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2002.09.045","article-title":"Quality of life of long-term survivors of non-small-cell lung cancer","volume":"20","author":"Sarna","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib121","first-page":"823","article-title":"The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial","volume":"10","author":"Khuri","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.esmoop.2022.100605_bib122","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0306-4603(93)90068-K","article-title":"Biochemical validation of smoking status: pros, cons, and data from four low-intensity intervention trials","volume":"18","author":"Glasgow","year":"1993","journal-title":"Addict Behav"},{"key":"10.1016\/j.esmoop.2022.100605_bib123","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2105\/AJPH.84.7.1086","article-title":"The validity of self-reported smoking: a review and meta-analysis","volume":"84","author":"Patrick","year":"1994","journal-title":"Am J Public Health"},{"key":"10.1016\/j.esmoop.2022.100605_bib124","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1200\/JCO.2013.50.9695","article-title":"Second-hand smoke as a predictor of smoking cessation among lung cancer survivors","volume":"32","author":"Eng","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100605_bib125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40463-019-0357-4","article-title":"The effect of second hand smoke in patients with squamous cell carcinoma of the head and neck","volume":"48","author":"Idris","year":"2019","journal-title":"J\u00a0Otolaryngol Head Neck Surg"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T09:26:31Z","timestamp":1718789191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":125,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2059702922002356"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100605","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100605"}}